{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-100960","form_type":"8-K","ticker":null,"cik":"0001567514","company_name":"Intra-Cellular Therapies, Inc.","filed_at":"2024-04-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.002139+00:00","generated_at":"2026-06-03T18:53:08.871321+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Intra-Cellular Therapies prices $500M public offering of 6.85M shares at $73.00 per share","bullets":["Gross proceeds of $500M from 6,849,316 shares at $73.00/share; net proceeds ~$472.1M after underwriting discounts and expenses.","Underwriters granted 30-day option to purchase up to 1,027,397 additional shares on same terms.","Offering expected to close April 22, 2024; J.P. Morgan, Leerink, BofA, Morgan Stanley, RBC acting as joint book-runners.","Company is selling all shares; no specific use of proceeds disclosed in the filing."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-100960","json":"https://secwatch.observer/filing/0001193125-24-100960.json","markdown":"https://secwatch.observer/filing/0001193125-24-100960.md","text":"https://secwatch.observer/filing/0001193125-24-100960.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1567514/000119312524100960/0001193125-24-100960-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1567514/000119312524100960/d816580d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T18:53:08.871321+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"af301ed5aaec471248621fdb93e0b7257454f1c9","claim":"Intra-Cellular Therapies, Inc. entered into Underwriting Agreement with J.P. Morgan Securities LLC, Leerink Partners LLC, BofA Securities, Inc., Morgan Stanley & Co. LLC and RBC Capital Markets, LLC, as representatives of the several underwriters named therein valued at approximately $472.1 million (effective 2024-04-17).","evidence_excerpt":"On April 17, 2024, Intra-Cellular Therapies, Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with J.P. Morgan Securities LLC, Leerink Partners LLC, BofA Securities, Inc., Morgan Stanley & Co. LLC and RBC Capital Markets, LLC, as representatives of the several underwriters named therein (collectively, the “ Underwriters ”), relating to an underwritten public offering of 6,849,316 shares (the “ Underwritten Shares ”) of the Company’s common stock","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1567514/000119312524100960/0001193125-24-100960-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"J.P. Morgan Securities LLC, Leerink Partners LLC, BofA Securities, Inc., Morgan Stanley & Co. LLC and RBC Capital Markets, LLC, as representatives of the several underwriters named therein"},{"label":"Value","value":"approximately $472.1 million"},{"label":"Effective","value":"2024-04-17"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}